NanoRepro AG (ETR: NN6)

Market Cap	22.82M
Revenue (ttm)	3.18M
Net Income (ttm)	-4.69M
Shares Out	12.71M
EPS (ttm)	-0.37
PE Ratio	n/a
Forward PE	n/a
Dividend	0.15 (8.17%)
Ex-Dividend Date	n/a

Volume	2,448
Open	1.830
Previous Close	1.835
Day's Range	1.755 - 1.830
52-Week Range	1.600 - 2.790
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 23, 2024

About NanoRepro AG

NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. It provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. The company offers rapid diagnostic tests, such as family planning, and preventive healthcare line products; tests for hospitals and medical practices to detect aids, Troponin I, D-dimer, streptococci antigen, influenza type A and B antigens, and mi...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2006
• Employees: 18
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: NN6

Financial Performance

In 2023, NanoRepro AG's revenue was 3.18 million, a decrease of -91.79% compared to the previous year's 38.79 million. Losses were -4.69 million, 25.8% more than in 2022.